	US 12,091,466 B2
	Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
Chakra Chaulagain, Broward, FL (US); Raymond Comenzo, Boston, MA (US); Parul Doshi, Spring House, PA (US); Xun Ma, Boston, MA (US); and Amy Sasser, Spring House, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US); and TUFTS MEDICAL CENTER, INC., Boston, MA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US); and Tufts Medical Center, Inc., Boston, MA (US)
Filed on Aug. 5, 2020, as Appl. No. 16/986,214.
Application 16/986,214 is a continuation of application No. 15/160,476, filed on May 20, 2016, granted, now 10,766,965.
Claims priority of provisional application 62/214,586, filed on Sep. 4, 2015.
Claims priority of provisional application 62/164,206, filed on May 20, 2015.
Prior Publication US 2020/0407459 A1, Dec. 31, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 31/664 (2006.01); A61K 31/69 (2006.01); A61K 38/05 (2006.01); A61K 38/47 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61K 9/0019 (2013.01); A61K 31/573 (2013.01); A61K 31/664 (2013.01); A61K 31/69 (2013.01); A61K 38/05 (2013.01); A61K 38/47 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12Y 302/01035 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01)]

18 Claims

1. A method of treating light chain amyloidosis (AL) in a newly diagnosed AL patient, comprising administering to the patient a pharmaceutical composition comprising an anti-CD38 antibody and a hyaluronidase for a time sufficient to treat the AL, wherein:

a) the anti-CD38 antibody is of an IgG1 isotype comprising a heavy chain variable region (VH) sequence of SEQ ID NO: 4 and a light chain variable region (VL) sequence of SEQ ID NO: 5;

b) the hyaluronidase is rHuPH20 recombinant hyaluronidase; and

c) the pharmaceutical composition is administered in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD).